Publications by authors named "Jon Travers"

Claim this Profile
A
Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells.
Shivam Vora, Saptarshi Chatterjee, Ariel Andrew, Ramyashree Prasanna Kumar, Martina Proctor, Jon Travers

Cell Death Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition.
Shivam Vora, Ariel Andrew, Ramyashree Prasanna Kumar, Deborah Nazareth, Alexis Bonfim-Melo, Jon Travers

Cell Death Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Kavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, C Allison Stewart, Qi Wang, Jon Travers

Clin Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, Sara Talbot, Rebecca Whiteley, Jon Travers

Mol Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors.
David B Chou, Brooke A Furlong, Ryan R Posey, Christos Kyprianou, Lucy R O'Sullivan, Jon Travers

Nat Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
James Harper, Shannon Burke, Jon Travers, Nicola Rath, Andrew Leinster

Mol Cancer Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of an Imidazo[1,2-]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with Efficacy.
William McCoull, Scott Boyd, Martin R Brown, Muireann Coen, Olga Collingwood, Jon Travers

J Med Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs.
Henry Gerdes, Pedro Casado, Arran Dokal, Maruan Hijazi, Nosheen Akhtar, Jon Travers

Nat Commun· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
Monique B Nilsson, Huiying Sun, Jacqulyne Robichaux, Matthias Pfeifer, Ultan McDermott, Jon Travers

Sci Transl Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade and .
Srimoyee Ghosh, Geeta Sharma, Jon Travers, Sujatha Kumar, Justin Choi

Mol Cancer Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.
Matthew G Oser, Raquel Fonseca, Abhishek A Chakraborty, Rachel Brough, Alexander Spektor, Jon Travers

Cancer Discov· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structured illumination microscopy combined with machine learning enables the high throughput analysis and classification of virus structure.
Romain F Laine, Gemma Goodfellow, Laurence J Young, Jon Travers, Danielle Carroll

Elife· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Sonja J Gill, Jon Travers, Irina Pshenichnaya, Fiona A Kogera, Syd Barthorpe

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair.
Takashi Ochi, Andrew N Blackford, Julia Coates, Satpal Jhujh, Shahid Mehmood, Jon Travers

Science· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design.
Sylvain Couty, Isaac M Westwood, Andrew Kalusa, Celine Cano, Jon Travers

Oncotarget· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shock about heat shock in cancer.
Emmanuel de Billy, Jon Travers, Paul Workman

Oncotarget· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
Jon Travers, Swee Sharp, Paul Workman

Drug Discov Today· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetics: Targeting leukemia on the DOT.
Jon Travers, Julian Blagg, Paul Workman

Nat Chem Biol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer: drug-tolerant insurgents.
Paul Workman, Jon Travers

Nature· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis